ClinicalTrials.gg
CompletedNCT01290757Updated May 19, 2014Results posted

Bioequivalence of Two Different Capsule Types of Dabigatran

A Phase 1 interventional study of Dabigatran etexilate and Dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

The objective of this Phase I trial is to demonstrate the bioequivalence of two capsules of dabigatran etexilate made from two different drug product batches.

The reference batch is dabigatran etexilate hard capsules 150 mg using the currently approved capsule shell (Qualicaps). The test batch is dabigatran etexilate 150 mg hard capsules using a new capsule shell (Capsugel). The test batch is the drug product intended for future commercial use.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), clinical laboratory tests
  2. Age =21 and = 55 years
  3. (BMI) =18.5 and BMI = 29.9 kg/m\^2
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion criteria:

  1. gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Clinically relevant surgery of gastrointestinal tract or evidence of significant gastrointestinal motility problems that could affect absorption of the drug
  3. Diseases of the central nervous system (included but not limited to any kind of seizures, stroke or psychiatric disorders) within the past 6 month
  4. Any history or evidence of blood dyscrasia, hemorrhagic diathesis, severe thrombocytopenia, cerebrovascular hemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with hemorrhagic tendencies
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of allergy/ (including drug allergy in particular to study drug or its ) which is deemed relevant to the trial as judged by the investigator
  8. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  9. Alcohol abuse (more than 20 g/day)
  10. Drug abuse
  11. Any laboratory value outside the reference range that is of clinical relevance (especially , , (PT) and Activated Partial Thromboplastin Time (Measure of the clotting time) (aPTT) or positive drug or virus screening
  12. Planned surgeries within four weeks following the end-of study examination
  13. Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding within 14 days before or after end-of study examination
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Dabigatran etexilate 150 mg (T)

    Capsugel (T), oral administration

    Drug: Dabigatran etexilate

  • Experimental
    Dabigatran etexilate 150 mg (R)

    Qualicaps (R), oral administration

    Drug: Dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran

    Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

    Time frame: 60 hours

  2. Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma

    Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

    Time frame: 60 hours

Secondary outcomes

  1. Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.

    Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

    Time frame: 60 hours

  2. AUC0-tz of Free Dabigatran.

    Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

    Time frame: 60 hours

  3. Cmax of Free Dabigatran in Plasma.

    Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

    Time frame: 60 hours

  4. AUC0-∞ of Free Dabigatran.

    Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

    Time frame: 60 hours

07

Results

Posted Jun 29, 2012

Participant flow

Participant flow — Overall Study
MilestoneSequence: Qualicaps - Capsugel - Qualicaps - CapsugelSequence: Capsugel - Qualicaps - Capsugel - Qualicaps
Started9090
Completed8888
Not completed22
Withdrew: Adverse event10
Withdrew: Protocol violation11
Withdrew: Other01

Outcome measures

PrimaryArea Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran

Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

Time frame:
60 hours
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran
ng*hr/mLCapsugelQualicaps
Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran1147.64 ± 32.32908.48 ± 49.83
Statistical analysis
  • Capsugel vs Qualicaps · Mixed Models Analysis · Upper 95% ci of the linearized criterion: -0.082Linearized regulatory criterion according to Tothfalusi et al (Pharmaceutical Research, 2001). The square of the difference in treatment responses divided by within-subject variance of the reference formulation minus square of ln(1.25)/0.25
  • Capsugel vs Qualicaps · Mixed Models Analysis · Adjusted geometric mean ratio (%): 126.33 · 90% CI 119.45 to 133.60
PrimaryMaximum Measured Concentration (Cmax) of Total Dabigatran in Plasma

Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

Time frame:
60 hours
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma
ng/mLCapsugelQualicaps
Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma134.44 ± 31.10107.13 ± 49.67
Statistical analysis
  • Capsugel vs Qualicaps · Mixed Models Analysis · Upper 95% ci of the linearized criterion: -0.085Linearized regulatory criterion according to Tothfalusi et al (Pharmaceutical Research, 2001). The square of the difference in treatment responses divided by within-subject variance of the reference formulation minus square of ln(1.25)/0.25
  • Capsugel vs Qualicaps · Mixed Models Analysis · Adjusted geometric mean ratio (%): 125.49 · 90% CI 118.69 to 132.67
SecondaryArea Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.

Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

Time frame:
60 hours
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.
ng*hr/mLCapsugelQualicaps
Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.1175.05 ± 30.81941.99 ± 46.53
Statistical analysis
  • Capsugel vs Qualicaps · Mixed Models Analysis · Adjusted geometric mean ratio (%): 124.74 · 90% CI 118.32 to 131.51
SecondaryAUC0-tz of Free Dabigatran.

Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

Time frame:
60 hours
Reported as:
Geometric mean · ng*hr/mL
AUC0-tz of Free Dabigatran.
ng*hr/mLCapsugelQualicaps
AUC0-tz of Free Dabigatran.856.31 ± 33.15678.43 ± 50.85
Statistical analysis
  • Capsugel vs Qualicaps · Mixed Models Analysis · Adjusted geometric mean ratio (%): 126.22 · 90% CI 119.36 to 133.47
SecondaryCmax of Free Dabigatran in Plasma.

Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

Time frame:
60 hours
Reported as:
Geometric mean · ng/mL
Cmax of Free Dabigatran in Plasma.
ng/mLCapsugelQualicaps
Cmax of Free Dabigatran in Plasma.106.66 ± 31.3485.12 ± 50.33
Statistical analysis
  • Capsugel vs Qualicaps · Mixed Models Analysis · Adjusted geometric mean ratio (%): 125.30 · 90% CI 118.42 to 132.59
SecondaryAUC0-∞ of Free Dabigatran.

Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.

Time frame:
60 hours
Reported as:
Geometric mean · ng*hr/mL
AUC0-∞ of Free Dabigatran.
ng*hr/mLCapsugelQualicaps
AUC0-∞ of Free Dabigatran.888.86 ± 31.20714.01 ± 47.16
Statistical analysis
  • Capsugel vs Qualicaps · Mixed Models Analysis · Adjusted geometric mean ratio (%): 124.49 · 90% CI 118.11 to 131.21

Adverse events

Collected over Approximately 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Qualicaps—0/180 (0%)37/180 (20.6%)
Capsugel—0/180 (0%)34/180 (18.9%)
Most frequent other events
Most frequent other events
EventQualicapsCapsugel
HeadacheNervous system disorders37/18034/180

Baseline characteristics

Treated set includes all patients who received at least one study treatment.

Age, Continuous
Age, Continuous(Years)Sequence: Qualicaps - Capsugel - Qualicaps - CapsugelSequence: Capsugel - Qualicaps - Capsugel - QualicapsTotal
Mean39.8 ± 10.139.4 ± 9.139.6 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Sequence: Qualicaps - Capsugel - Qualicaps - CapsugelSequence: Capsugel - Qualicaps - Capsugel - QualicapsTotal
Female464793
Male444387
08

Study locations

1 site
  • 1160.117.1 Boehringer Ingelheim Investigational Site
    Mannheim, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011 and a primary completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2011
First posted
Feb 7, 2011
Start
Jan 2011
Primary completionActual
Apr 2011
Results first posted
Jun 29, 2012
Last update
May 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01290757
Responsible party
Sponsor
First posted
Feb 7, 2011
Start date
Jan 2011
Primary completion
Apr 2011
Results posted
Jun 29, 2012
Last update
May 19, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion